Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H29N3O2.ClH |
Molecular Weight | 415.956 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(C=C1OC)C(CCN3CCN(CC3)C4=CC=CC=C4)=C(C)N2
InChI
InChIKey=USAPVNXIZYFWLO-UHFFFAOYSA-N
InChI=1S/C23H29N3O2.ClH/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18;/h4-8,15-16,24H,9-14H2,1-3H3;1H
Molecular Formula | C23H29N3O2 |
Molecular Weight | 379.4953 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/5322447Curator's Comment: Description was created based on several sources, including http://imr.sagepub.com/content/1/6/573.full.pdf
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5322447
Curator's Comment: Description was created based on several sources, including http://imr.sagepub.com/content/1/6/573.full.pdf
Oxypertine (Equipertine, Forit, Integrin, Lanturil, Lotawin, Opertil) is a neuroleptic drug and was originally introduced as a treatment for schizophrenia in the 1960s. Oxypertine is an indole derivative with general properties similar to those of the phenothiazine, chlorpromazine. It has been given by mouth in the treatment of various psychoses including schizophrenia, mania, and disturbed behaviour, and of severe anxiety. Like reserpine and tetrabenazine, oxypertine depletes catecholamines, though not serotonin, possibly underlying its neuroleptic efficacy. The molecular structure is strongly similar to solypertine and milipertine.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5588334
Curator's Comment: Oxypertine penetrates the blood-brain barrier in mice and cats
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja00866a050
Curator's Comment: Oxypertine was first synthesized by Archer et al
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907610 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084 |
54.0 nM [IC50] | ||
Target ID: CHEMBL2093868 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084 |
210.0 nM [IC50] | ||
Target ID: CHEMBL2095179 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084 |
|||
Target ID: Serotonin receptors Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084 |
25.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | FORIT Approved UseOxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia. |
|||
Primary | FORIT Approved UseOxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia. |
PubMed
Title | Date | PubMed |
---|---|---|
Biochemical versus psychopathological action profile of neuroleptics: a comparative study of chlorpromazine and oxypertine in acute psychotic disorders. | 1975 May-Jun |
|
Enhanced separation of filamentous fungi by ultrasonic field: possible usage in repeated batch processes. | 2002 Aug 7 |
|
Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. | 2003 Dec 25 |
|
Towards pick-and-place assembly of nanostructures. | 2004 Mar |
|
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. | 2004 Nov 26 |
|
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. | 2010 Mar 3 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9125
Oxypertine 20 mg given orally as a nocturnal sedative and again on the morning of operation produced relief of anxiety
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6107084
Oxypertine inhibited [3H]WB-4101 binding in rat cerebral cortex membranes with IC50 54 nM
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:35:35 GMT 2023
by
admin
on
Sat Dec 16 01:35:35 GMT 2023
|
Record UNII |
9P131473P6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
17506-66-0
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY | |||
|
SUB03592MIG
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY | |||
|
169107
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY | |||
|
DTXSID6048751
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY | |||
|
9P131473P6
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY | |||
|
100000085511
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY | |||
|
38510
Created by
admin on Sat Dec 16 01:35:35 GMT 2023 , Edited by admin on Sat Dec 16 01:35:35 GMT 2023
|
PRIMARY |